Fibrates: where are we now?VA Medical Center, North Chicago, Illinois, USA
VA Medical Center, North Chicago, Illinois, USA Rohit.arora{at}med.va.gov Cardiovascular disease remains a leading cause of mortality worldwide. As dyslipidemia increases cardiovascular disease risk, proper management of dyslipidemia is one means by which to decrease cardiovascular disease risk. This review focuses on dyslipidemia treatment utilizing fibrate therapy, which targets high trigylcerides, low HDL, and high small, dense LDL, while contrasting fibrate therapy with statin therapy and combined therapy. Studies were obtained using electronic search strategies, such as Medline and Cochrane Library. Sources selected were limited to those that discussed fibrates, statins, and combined therapy, with specific emphasis placed on sources that focused on fibrates. Selected studies were then assessed for quality via analysis of the study's methodology, results, and data. Results of selected studies were then stratified using a rating system devised to determine the quality of results using the scientific evidence provided for them. Combination fibrate and statin therapy can be more effective in achieving optimal lipid levels than just fibrate or statin therapy alone without significant side effects as long as gemfibrozil is not used in therapy.
Key Words: cardiovascular disease • cardiovascular disease risk • fibrate therapy • statin therapy • dyslipidemia • high-density lipoprotein
Therapeutic Advances in Cardiovascular Disease, Vol. 3, No. 1,
91-96 (2009) |
|||||
